Related references
Note: Only part of the references are listed.Complete revascularization optimizes patient outcomes in multivessel coronary artery disease: Data from the e-Ultimaster registry
Timothy Williams et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2022)
The Ongoing Saga of the Evolution of Percutaneous Coronary Intervention: From Balloon Angioplasty to Recent Innovations to Future Prospects
Fabien Picard et al.
CANADIAN JOURNAL OF CARDIOLOGY (2022)
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents
David E. Kandzari et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2022)
Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy
Aleena Mary Cherian et al.
APL BIOENGINEERING (2021)
The third generation of drug-eluting stents: Reassuring data while we wait for the next one COMMENT
Sergio Bravo Baptista
REVISTA PORTUGUESA DE CARDIOLOGIA (2021)
Primary Results of the EVOLVE Short DAPT Study Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent
Ajay J. Kirtane et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2021)
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI
Thomas Pilgrim et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2021)
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Marco Valgimigli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial
Manel Sabate et al.
EUROINTERVENTION (2021)
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
S. Windecker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention The SORT OUT IX Trial
Lisette Okkels Jensen et al.
CIRCULATION (2020)
10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents
Sebastian Kufner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
FINAL 5-YEAR OUTCOMES OF THE EVOLVE II TRIAL: A PROSPECTIVE RANDOMIZED INVESTIGATION OF A NOVEL BIOABSORBABLE POLYMER-COATED, EVEROLIMUS-ELUTING SYNERGY STENT
Dean J. Kereiakes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention
Michael Maeng et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2019)
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention A Subgroup Analysis of the BIOSCIENCE Randomized Trial
Juan F. Iglesias et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2019)
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
Juan F. Iglesias et al.
LANCET (2019)
Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?
Mateusz P. Jezewski et al.
JOURNAL OF CLINICAL MEDICINE (2019)
BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months
Shigeru Saito et al.
EUROINTERVENTION (2019)
In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial
Hector M. Garcia-Garcia et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?
Aurelien de Pommereau et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2018)
Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery
Micaela Iantorno et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial
Clemens von Birgelen et al.
LANCET (2018)
The Newest Generation of Drug-eluting Stents and Beyond
Dae-Hyun Lee et al.
EUROPEAN CARDIOLOGY REVIEW (2018)
The evolution of coronary stents
Peter McKavanagh et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2018)
Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial
Matthew J. Price et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2018)
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent The RESOLUTE Global Clinical Trial Program
Robert W. Yeh et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease 5-Year Results From the PLATINUM Trial
Christopher R. Kelly et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2017)
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds The ABSORB III Trial
Dean J. Kereiakes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial
David E. Kandzari et al.
LANCET (2017)
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
Joanna J. Wykrzykowska et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Giovanna Sarno et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2017)
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial
Clemens von Birgelen et al.
LANCET (2016)
Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent The EVOLVE II Randomized Trial
Dean J. Kereiakes et al.
Circulation-Cardiovascular Interventions (2015)
Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation An Individual Patient Data Pairwise and Network Meta-Analysis
Tullio Palmerini et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial
Bent Raungaard et al.
LANCET (2015)
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Philip Urban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model
Fumiyuki Otsuka et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2014)
A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial
Shigeru Saito et al.
EUROPEAN HEART JOURNAL (2014)
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial
Clemens von Birgelen et al.
LANCET (2014)
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Thomas Pilgrim et al.
LANCET (2014)
Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomized, Noninferiority Trial
Patrick W. Serruys et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial
Yoshinobu Onuma et al.
EUROINTERVENTION (2013)
Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV)
Lisette Okkels Jensen et al.
CIRCULATION (2012)
Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography
Hyun Hee Choi et al.
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2012)
Primary Endpoint Results of the EVOLVE Trial A Randomized Evaluation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent
Ian T. Meredith et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients The TWENTE Trial
Clemens von Birgelen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease The Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Trial
Steffen Massberg et al.
CIRCULATION (2011)
Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents Final 5-Year Analysis From the TAXUS Clinical Trial Program
Gregg W. Stone et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
David E. Kandzari et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Design principles and performance of bioresorbable polymeric coronary scaffolds
James Oberhauser et al.
EuroIntervention (2011)
Everolimus-eluting stents: update on current clinical studies
Dominic J. Allocco et al.
MEDICAL DEVICES-EVIDENCE AND RESEARCH (2011)
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
Stephan Windecker et al.
LANCET (2008)
The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents
Gaku Nakazawa et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Pathology of drug-eluting stents in humans - Delayed healing and late thrombotic risk
Michael Joner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Zotarolimus (ABT-578) eluting stents
Sandra E. Burke et al.
ADVANCED DRUG DELIVERY REVIEWS (2006)
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions - The REALITY trial: A randomized controlled trial
MC Morice et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease - A randomized controlled trial
GW Stone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis -: A randomized controlled trial
A Kastrati et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery
JW Moses et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Intracoronary stenting and angiographic results:: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial
J Pache et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
M Morice et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
